Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Trillium Therapeutics - The "Don't Eat Me" Cure For Cancer

|Includes: PCYC, Trillium Therapeutics Inc. (TRIL)

SkyTides releases new report on Trillium Therapeutics (NASDAQ:TRIL). In its initial research report SkyTides presents its findings:

  • Immunotherapy cancer treatments - new hope in the quest to cure cancers
  • Anti-CD47 therapies one of most promising immunotherapy niches
  • Stanford and Trillium studies suggest anti-CD47 could treat many cancers
  • Trillium's SIRPαFc only known CD47 treatment that targets cancer cells with limited effect on healthy red blood cells
  • SIRPαFc Phase 1 clinical study scheduled to begin 2H 2015
  • Institutional investors own 70% of Trillium
  • NASDAQ listing approval in December 2014
  • Price target $41.67

To download the Report (PDF format), click on the link below.

Use of SkyTides research reports is limited by the Terms of Service on its website, which are as follows. To be authorized to access such reports, you must agree to these terms, regardless of whether you have downloaded its reports directly from this website or someone else has supplied the report to you without authorization.

Terms of Service:

By downloading from, or viewing material on, this website you agree to the following Terms of Service. You agree that use of SkyTides LLC's research is at your own risk. In no event will you hold SkyTides LLC or any affiliated party liable for any direct or indirect trading losses caused by any information on this site. You further agree to do your own research and due diligence before making any investment decision with respect to securities covered herein. You represent to SkyTides that you have sufficient investment sophistication to critically assess the information, analysis and opinion on this site. You further agree that you will not communicate the contents of this report to any other person unless that person has agreed to be bound by these same terms of service. If you download or receive the contents of this report as an agent for any other person, you are binding your principal to these same Terms of Service. You should assume that as of the publication date of our reports and research, SkyTides, LLC (possibly along with or through our members, partners, affiliates, employees, and/or consultants) along with our clients and/or investors and/or their clients and/or investors has a long or short position in all stocks (and/or options, swaps, and other derivatives related to the stock) and bonds covered herein, and therefore stands to realize significant gains in the event that the price of either increases or declines. We may also have previously purchased shares of the stocks we discuss in our research in private transactions, which you acknowledge are generally completed at a discount to market prices. We intend to continue transacting in the securities of issuers covered on this site for an indefinite period after our first report, and we may be long, short, or neutral at any time hereafter regardless of our initial recommendation. This is not an offer to sell or a solicitation of an offer to buy any security, nor shall SkyTides LLC offer, sell or buy any security to or from any person through this site or reports on the SkyTides website at SkyTides, LLC is not registered as an investment advisor in any jurisdiction. You acknowledge that the author(s) of any publication released by SkyTides LLC at or do not hold any accreditation such as the Chartered Financial Analyst designation, or other comparable designations, to perform any valuation services related to any investment opportunity discussed by SkyTides LLC. If you are in the United Kingdom, you confirm that you are accessing research and materials as or on behalf of: (a) an investment professional falling within Article 19 of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the "FPO"); or (b) high net worth entity falling within Article 49 of the FPO. Our research and reports express our opinions, which we have based upon generally available information, field research, communications with management (only when specifically indicated), inferences and deductions through our due diligence and analytical process. To the best of our ability and belief, all information contained herein is accurate and reliable, and has been obtained from public sources we believe to be accurate and reliable, and who are not insiders or connected persons of the stock covered herein or who may otherwise owe any fiduciary duty or duty of confidentiality to the issuer, unless otherwise specifically indicated. However, such information is presented "as is," without warranty of any kind, whether express or implied. SkyTides, LLC makes no representation, express or implied, as to the accuracy, timeliness, or completeness of any such information or with regard to the results to be obtained from its use. Further, any report on this site contains a very large measure of analysis and opinion. All expressions of opinion are subject to change without notice, and SkyTides, LLC does not undertake to update or supplement any reports or any of the information, analysis and opinion contained in them. You agree that the information on this website is copyrighted, and you therefore agree not to distribute this information (whether the downloaded file, copies / images / reproductions, or the link to these files) in any manner other than by providing the following link: If you have obtained SkyTides research in any manner other than by download from the SkyTides website at, you may not read such research without going to that link and agreeing to the Terms of Service. You further agree that any dispute arising from your use of this report and / or the SkyTides website or viewing the material hereon shall be governed by the laws of the country of Nevis, without regard to any conflict of law provisions. You knowingly and independently agree to submit to the personal and exclusive jurisdiction of the courts located within the country of Nevis and waive your right to any other jurisdiction or applicable law, given that the registered office of SkyTides, LLC is in Charlestown, Nevis. The failure of SkyTides, LLC to exercise or enforce any right or provision of these Terms of Service shall not constitute a waiver of this right or provision. If any provision of these Terms of Service is found by a court of competent jurisdiction to be invalid, the parties nevertheless agree that the court should endeavor to give effect to the parties' intentions as reflected in the provision and rule that the other provisions of these Terms of Service remain in full force and effect, in particular as to this governing law and jurisdiction provision. You agree that regardless of any statute or law to the contrary, any claim or cause of action arising out of or related to use of this website or the material herein must be filed within one (1) year after such claim or cause of action arose or be forever barred.

Disclosure: The author has no positions in any stocks mentioned, but may initiate a long position in TRIL over the next 72 hours.